Subgroup Could Give Xpovio Focused Commercial Opportunity In Endometrial Cancer

Although Karyopharm Therapeutics’s Phase III SIENDO trial of Xpovio (selinexor) technically achieved its primary endpoint with a statistically significant gain in median progression-free survival (PFS), the benefit was modest compared to the improvement among patients with wild-type p53, suggesting the drug could see its biggest commercial opportunity in the subgroup.

The company said 8 February that SIENDO had met its primary endpoint of a statistically significant improvement in PFS versus placebo, as well as in the prespecified subgroup of patients with wild-type p53, a protein also known as “guardian of the genome